Eli Lilly and Company: Prostatic Neoplasms trials
The registry lists 20 Prostatic Neoplasms studies with Eli Lilly and Company as lead sponsor. 2 are open to participants now and 13 have results posted.
Phase 1 7Phase 2 10Phase 3 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY4257496 in Participants With Cancer (OMNIRAY)RecruitingNCT07114601Phase 1
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 1
- A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)Active, not recruitingNCT05288166Phase 3Results posted
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentActive, not recruitingNCT04647526Phase 3Results posted
- Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate CancerCompletedNCT04408924Phase 2Results posted
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerActive, not recruitingNCT03706365Phase 2/3Results posted
- A Study of Enzalutamide and LY3023414 in Men With Prostate CancerCompletedNCT02407054Phase 2Results posted
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
- A Study of Olaratumab (IMC-3G3) in Prostate CancerCompletedNCT01204710Phase 2Results posted
- A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and NeckCompletedNCT01059643Phase 2Results posted
- A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate CancerCompletedNCT00683475Phase 2Results posted
- A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate CancerCompletedNCT00642018Phase 2Results posted
- Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate CancerCompletedNCT00520481Phase 2Results posted
- A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer PatientsCompletedNCT00466440Phase 2Results posted
- Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and ChemotherapyCompletedNCT00428714Phase 2Results posted
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
- [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT06229366Phase 1
- Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentTerminatedNCT05999968Phase 1
- Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT04521686Phase 1
- An Expanded Access Program for AM0010 (Pegilodecakin)No longer availableNCT03554434